PEPTIDE: FOXO4-DRI

FOXO4-DRI is a 46-residue D-retro-inverso peptide engineered to disrupt a specific survival interaction in senescent cells.

In aging tissue, cells that suffer irreparable DNA damage enter a state of permanent growth arrest called senescence. These cells avoid death by using the FOXO4 protein to sequester the tumor suppressor p53 inside PML (Promyelocytic Leukemia) nuclear bodies. Trapped there, p53 cannot trigger apoptosis.

FOXO4-DRI mimics the FOXO4 binding interface and acts as a competitive antagonist. It binds the p53 TAD2 domain (Transactivation Domain 2) with higher affinity for the 'scarred' phosphorylation state found in senescent cells, specifically at Ser46 and Thr55.

When FOXO4-DRI displaces endogenous FOXO4, p53 is excluded from the nucleus and translocates to the mitochondria, initiating MOMP (Mitochondrial Outer Membrane Permeabilization) and BAX-mediated intrinsic apoptosis.

This mechanism is self-limiting: as the senescent cell pool depletes, the therapeutic target disappears. No chronic dose escalation is needed.

The foundational 2017 study by Baar et al. (Cell) demonstrated systemic rejuvenation in both naturally aged mice and XpdTTD/TTD progeroid models:

• Lifespan extension: 24.8-29% increase in median survival

• Dermal rejuvenation: Regrowth of fur and restoration of natural pigmentation

• Physical fitness: Significant increase in voluntary running wheel activity

• Senescent cell clearance: ~70% reduction in SA-beta-galactosidase positive cells

Fur regrowth is more than cosmetic. It serves as a clinical marker for rejuvenation of the dermal niche, where clearing SASP-secreting cells allows hair follicle stem cells to resume regenerative cycling.